CollPlant’s Collink.3D shows strong performance vs. Matrigel in study

CollPlant Biotechnologies (CLGN) announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D, and Matrigel, conducted by the Levenberg Lab at Technion – Israel Institute of Technology. Matrigel, developed and marketed by Corning (GLW), has been one of the most widely used extracellular matrices for more than three decades. Derived from the Engelbreth-Holm-Swarm mouse sarcoma, it contains a rich combination of basement membrane proteins such as laminin, collagen IV, heparan sulfate proteoglycans, and entactin/nidogen, as well as growth factors that make it a cornerstone for 3D cell culture, disease modeling, and drug discovery. In the Technion study, Collink.3D demonstrated enhanced mechanical strength, elasticity, and stability, providing a reproducible environment that supports organized and long-lasting tissue formation. These results suggest that Collink.3D may serve as a next-generation, animal-free extracellular matrix, offering a complementary approach to traditional matrices such as Matrigel.